AU2001264801A1 - Diagnosis of alzheimer's disease ldl receptor protein-1 - Google Patents

Diagnosis of alzheimer's disease ldl receptor protein-1

Info

Publication number
AU2001264801A1
AU2001264801A1 AU2001264801A AU6480101A AU2001264801A1 AU 2001264801 A1 AU2001264801 A1 AU 2001264801A1 AU 2001264801 A AU2001264801 A AU 2001264801A AU 6480101 A AU6480101 A AU 6480101A AU 2001264801 A1 AU2001264801 A1 AU 2001264801A1
Authority
AU
Australia
Prior art keywords
disease
alzheimer
brain
diagnosis
receptor protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001264801A
Inventor
Berislav V. Zlokovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of AU2001264801A1 publication Critical patent/AU2001264801A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Brain endothelial low-density lipoprotein receptor related protein-1 (LRP-1) mediates vascular clearance of Alzheimer's amyloid-β peptide (Aβ) from the brain. Transport of Aβ occurs across the blood-brain barrier (BBB) to the systemic circulation, but the brain endothelium is compromised in Alzheimer's disease. The invention is used to diagnose the disease in symptomatic and asymptomatic individuals, to identify those at risk for disease or already affected thereby, to determine the stage of disease or its progression, to intervene earlier in or alter the disease's natural history, to provide a target for therapeutic or prophylactic treatments, to screen drugs or compare medical regimens, to determine the effectiveness of a drug or medical regimen, or any combination thereof.
AU2001264801A 2000-05-23 2001-05-23 Diagnosis of alzheimer's disease ldl receptor protein-1 Abandoned AU2001264801A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20642800P 2000-05-23 2000-05-23
US60/206,428 2000-05-23
US24626800P 2000-11-06 2000-11-06
US60/246,268 2000-11-06
PCT/US2001/016561 WO2001090758A2 (en) 2000-05-23 2001-05-23 Diagnosis of alzheimer's disease ldl receptor protein-1

Publications (1)

Publication Number Publication Date
AU2001264801A1 true AU2001264801A1 (en) 2001-12-03

Family

ID=26901346

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001264801A Abandoned AU2001264801A1 (en) 2000-05-23 2001-05-23 Diagnosis of alzheimer's disease ldl receptor protein-1

Country Status (8)

Country Link
US (2) US7695903B2 (en)
EP (1) EP1290451B1 (en)
JP (1) JP4851676B2 (en)
AT (1) ATE312354T1 (en)
AU (1) AU2001264801A1 (en)
CA (1) CA2408566A1 (en)
DE (1) DE60115638T2 (en)
WO (1) WO2001090758A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
WO2001090758A2 (en) * 2000-05-23 2001-11-29 The University Of Southern California Diagnosis of alzheimer's disease ldl receptor protein-1
AU2003253014A1 (en) * 2002-06-21 2004-01-06 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
US7608586B2 (en) * 2003-06-11 2009-10-27 The University Of Rochester Soluble low-density lipoprotein receptor related protein binds directly to Alzheimer's amyloid-beta peptide
ES2332846B1 (en) * 2007-10-26 2010-07-08 Grifols, S.A. USE OF THERAPEUTIC HUMAN ALBUMIN FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS AFFECTED BY COGNITIVE DISORDERS.
US8946165B2 (en) * 2008-09-29 2015-02-03 The Regents Of The University Of California Compounds for reversing and inhibiting protein aggregation, and methods for making and using them
AU2010307332A1 (en) * 2009-10-17 2012-05-17 Zz Alztech L.L.C. Mutant low-density lipoprotein receptor related protein with increased binding to Alzheimer amyloid-beta peptide
CN110192859B (en) * 2019-05-05 2020-05-19 兰月 Method for measuring human brain lymph-like pathway clearing efficiency by magnetic resonance
KR102549828B1 (en) * 2021-03-22 2023-07-04 경희대학교 산학협력단 Blood Brain Barrier-On-a-Chip

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202424A (en) * 1984-03-19 1993-04-13 The Rockefeller University Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof
US4758583A (en) * 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US4900747A (en) * 1984-03-19 1990-02-13 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
US5766856A (en) * 1984-03-19 1998-06-16 The Picower Institute For Medical Research Diagnostic method for evaluating advanced glycosylation endproducts using MAC-2 receptor
EP0582143B1 (en) * 1992-07-22 1998-11-04 THE McLEAN HOSPITAL CORPORATION Methods for detecting Alzheimer's disease
US6410598B1 (en) * 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5962245A (en) * 1995-04-05 1999-10-05 The Picower Institute For Medical Research Methods for detecting the presence of advanced glycosylation endproducts
US6156311A (en) * 1995-07-27 2000-12-05 The American National Red Cross Modulators of expression and function of LRP in alzheimer's disease
WO1997004794A1 (en) * 1995-07-27 1997-02-13 The American National Red Cross Modulators of expression and function of lrp in alzheimer's disease
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US6472140B1 (en) * 1997-09-05 2002-10-29 The General Hospital Corporation α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
US6413512B1 (en) * 1998-02-13 2002-07-02 National Enzyme Company Composition and method for treating disease by increasing activated α2 macroglobulin in the blood and extravascular tissue
WO2001090758A2 (en) * 2000-05-23 2001-11-29 The University Of Southern California Diagnosis of alzheimer's disease ldl receptor protein-1
US6825164B1 (en) 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
WO2002057496A2 (en) * 2001-01-18 2002-07-25 Socratech L.L.C. Gene expression profiling of endothelium in alzheimer's disease
AU2003248660A1 (en) * 2002-06-11 2003-12-22 Socratech, L.L.C. Treatment of vascular dysfunction and alzheimer's disease

Also Published As

Publication number Publication date
CA2408566A1 (en) 2001-11-29
WO2001090758A3 (en) 2002-08-29
DE60115638D1 (en) 2006-01-12
ATE312354T1 (en) 2005-12-15
DE60115638T2 (en) 2006-08-17
JP2004510957A (en) 2004-04-08
EP1290451A2 (en) 2003-03-12
WO2001090758A2 (en) 2001-11-29
US20050239062A1 (en) 2005-10-27
US20040259159A1 (en) 2004-12-23
EP1290451B1 (en) 2005-12-07
JP4851676B2 (en) 2012-01-11
US7695903B2 (en) 2010-04-13

Similar Documents

Publication Publication Date Title
Mourad et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach
Feldman et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals
BG104075A (en) Combined treatment including atorvastatin and an antihypertonic form
AU2001264801A1 (en) Diagnosis of alzheimer's disease ldl receptor protein-1
CA2468771A1 (en) Pharmaceutical composition for use in ophthalmology and rhinology
EP2305282A3 (en) Prevention and treatment of amyloidogenic disease
WO2002057496A3 (en) Gene expression profiling of endothelium in alzheimer's disease
HUP0301729A2 (en) Remedies for heart failure
EE200100645A (en) Prevention and treatment of amyloidogenic disease
DE60003160D1 (en) COMBINATIONS OF FORMOTEROL AND MOMETASONFUROAT
HUP0203590A2 (en) Remedies for diseases in association with decrease in bone mass
Hiatt et al. Efficacy and tolerability of the novel fast skeletal muscle troponin activator, CK-2017357, in patients with claudication
BRPI0404050A (en) Use of a compound or pharmaceutically acceptable salt or ester thereof, pharmaceutical formulation, packaged formulation, compound, and method for preventing and / or treating benign prostate hyperplasia in patients in need of such prevention or treatment.
Kocsis et al. Pharmacotherapy for ‘pure’dysthymia: setraline vs. imipramine and placebo
Glasser et al. The efficacy and safety of once-daily nifedipine: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate diastolic hypertension
Clarke et al. Potentially serious drug interactions secondary to high‐dose diltiazem used in the treatment of pulmonary hypertension
DE50005282D1 (en) MEDICINE AND MATCHED COMBINATION OF MEDICINES
Israili The use of calcium antagonists in the therapy of hypertension in the elderly
Mahavadi Autophagy in Amiodarone induced Lung Fibrosis: A Close Look
Richardson Can physicians effect persistent control of blood pressure?
Vilas et al. MANAGEMENT OF JANU SANDHISHULA BY RAKTAMOKSHANA THROUGH JALAUKAVACHARANA
Rocha-Gonsalves et al. First clinical experience with isradipine in the treatment of hypertension in Portugal
Edmonds et al. ACE inhibitor versus beta-blocker in the treatment of essential hypertension
Carlson Update of trials involving new treatments for stroke
de'Clari et al. Ciprofloxacin Was the Culprit: Not Itraconazole [with Reply]